Anatomy-based traffic lights missed important dose changes during lung radiotherapy
In 604 fractions, traffic-light alerts partially identified target undercoverage but were unreliable proxies for organ-at-risk dose changes.
Tag
nsclc
Robust optimization minimized lung-dose trade-offs in carbon-ion planning for stage I NSCLC
Robust optimization improved target coverage with less lung-dose penalty than margin expansion, while density override was particularly useful for solid tumors.
Deep learning generated CT-free PET with near-zero SUV bias in NSCLC
Emission-only PET synthesis produced 0.72% SUVmax bias and 99.2% contrast recovery in an independent NSCLC test cohort.
Time-series CT radiomics predicted rib fracture after lung SBRT with 0.79 validation AUC
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
Longitudinal muscle loss and myocardial remodeling tracked worse survival after non-small cell lung cancer radiotherapy
Skeletal muscle loss and substantial left ventricular mass changes on follow-up imaging were strongly associated with poorer survival after curative radiotherapy.
AI-derived LAD dose reproduced survival stratification in RTOG 0617
Automated LAD contours reproduced the association between coronary dose and survival in 460 stage III NSCLC patients, although performance varied by model.
Hybrid CT features predicted symptomatic pneumonitis after locally advanced NSCLC radiotherapy
A hybrid peri-tumoural CT model achieved an external AUC of 0.828 for predicting grade 2 or higher radiation pneumonitis.
Two-dimensional TCP modeling linked lung tumour control mainly to radiosensitivity heterogeneity
Inter-patient radiosensitivity explained 85–97% of modeled TCP steepness, while uncertainty in delivered dose exceeded uncertainty in local-control estimates.
Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Respiratory gating reduced lung SBRT target volumes and normal-tissue dose
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
Cardiac-dose model validated non-cancer death risk in one lung SBRT cohort
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Immune-sparing lung SBRT planning reduced lymphocyte loss in a randomized phase II trial
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
ESTRO defines clinical standards for high-dose thoracic reirradiation in NSCLC
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
Consolidative and salvage primary-tumour SABR showed similar outcomes in stage IV NSCLC
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.